The glycoprotein IIb/IIIa receptor inhibitor (abciximab) in ST-segment elevation myocardial infarction.
A successful therapy is presented using the antiplatelet agent abciximab, alone, in an ST-segment elevation acute myocardial infarction. The patient was treated in a center with permanent catheterization facilities. Clinical trials are necessary to validate the efficacy and the cost-effectiveness of this clinical decision and therapeutic option.